Acumen Pharmaceuticals, Inc. ( (ABOS) ) has released its Q3 earnings. Here is a breakdown of the information Acumen Pharmaceuticals, Inc.

In recent years, the focus of clinical development has been on immunotherapeutic compounds aimed at clearing brain ...

Alzheimer's disease is the most common cause of dementia in the elderly and is characterized by abnormal deposits of amyloid-beta and tau proteins in the brain. This disease has a ...

The drug works by removing accumulated amyloid beta proteins in the brain, slowing the progress of the disease. Those ...

single-injection once-monthly antibody delivered subcutaneously for the treatment of Alzheimer's disease that targets a key epitope at the N-terminus of amyloid beta (Aß) with high binding potency.

NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble ...

Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

In a major discovery, scientists have presented the first evidence of Alzheimer's disease transmission in living individuals.

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Leqembi’s sales continue to be underwhelming, according to analysts, who contend the companies’ Alzheimer’s disease therapy ...

But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and ...

Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.